Tiziana Life Sciences (TLSA) CEO buys 321,423 shares via trust

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd Chief Executive Officer Ivor Elrifi, through a trust, purchased a total of 321,423 shares of common stock in two open-market or private transactions. The trust bought 237,616 shares at $1.00 per share on August 5, 2026 and 83,807 shares at $0.97 per share on August 4, 2026. The holdings are reported as indirect, "By trust", and the Rule 10b5-1 trading-plan checkbox is not marked.

Insider Trade Summary

Net Buyer: 321,423 shares

Net Buy 2 txns

Insider Elrifi Ivor

Role Chief Executive Officer

Bought 321,423 shs ($319K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	237,616	$1.00	$238K
Purchase	COMMON STOCK	83,807	$0.97	$81K

Holdings After Transaction: COMMON STOCK — 4,793,684 shares (Indirect, By trust)

Key Figures

Shares purchased on 2026-08-05: 237,616 shares Purchase price on 2026-08-05: $1.00 per share Shares purchased on 2026-08-04: 83,807 shares +2 more

5 metrics

Shares purchased on 2026-08-05 237,616 shares Indirect purchase of common stock by trust on August 5, 2026

Purchase price on 2026-08-05 $1.00 per share Price paid per share for 237,616 indirectly held shares

Shares purchased on 2026-08-04 83,807 shares Indirect purchase of common stock by trust on August 4, 2026

Purchase price on 2026-08-04 $0.97 per share Price paid per share for 83,807 indirectly held shares

Total shares purchased 321,423 shares Aggregate net purchases reported across both transactions

Key Terms

nature of ownership, By trust, Purchase in open market or private transaction

3 terms

nature of ownership financial

"Field 'nature_of_ownership' states the nature of ownership for each entry"

By trust financial

"nature_of_ownership: "By trust" for both insider purchase transactions"

Purchase in open market or private transaction financial

"transaction_code_description: "Purchase in open market or private transaction""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 09:30 AM Accepted by SEC EDGAR 08/06/2026 - 09:30 AM Learn about SEC filing dates

FAQ

What insider transactions did TLSA CEO Ivor Elrifi report?

CEO Ivor Elrifi reported buying 321,423 TLSA shares indirectly via a trust in two transactions. The purchases occurred on August 4 and 5, 2026 as open-market or private transactions at prices between $0.97 and $1.00 per share.

How many TLSA shares were bought on August 5, 2026 and at what price?

On August 5, 2026, a trust associated with CEO Ivor Elrifi bought 237,616 TLSA common shares. The reported purchase price was $1.00 per share in an open-market or private transaction, and the ownership is classified as indirect, held by trust.

What TLSA share purchase did the CEO’s trust make on August 4, 2026?

On August 4, 2026, the trust associated with the CEO bought 83,807 TLSA common shares. The transaction is reported as a purchase in an open-market or private transaction at a price of $0.97 per share, with ownership noted as indirect, by trust.

Are the recent TLSA insider purchases by the CEO direct or indirect holdings?

The reported 321,423 TLSA shares acquired are held as indirect ownership. Each transaction lists the nature of ownership as "By trust", meaning the shares are held through a trust rather than directly by CEO Ivor Elrifi.

Were TLSA CEO Ivor Elrifi’s share purchases made under a Rule 10b5-1 plan?

The transactions are not identified as made under a Rule 10b5-1 plan. The document-level Rule 10b5-1 checkbox is marked false, indicating these reported purchases by the CEO’s trust are not affirmed as plan-based trades.

What is the total net insider buying reported for TLSA in this disclosure?

The disclosure shows net insider buying of 321,423 TLSA shares by CEO Ivor Elrifi’s trust. There are two purchase transactions and no reported sales, according to the transaction summary data included with the report.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elrifi Ivor

(Last) (First) (Middle)

535 BOYLSTON STREET

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tiziana Life Sciences Ltd [ TLSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	08/04/2026		P		83,807	A	$0.97	4,556,068	I	By trust
COMMON STOCK	08/05/2026		P		237,616	A	$1	4,793,684	I	By trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Ivor Elrifi	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)